Cargando…

Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease

BACKGROUND: Abnormal insulin signaling in the brain has been linked to Alzheimer’s disease (AD). OBJECTIVE: To evaluate whether cerebrospinal fluid (CSF) insulin levels are associated with cognitive performance and CSF amyloid-β and Tau. Additionally, we explore whether any such association differs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geijselaers, Stefan L.C., Aalten, Pauline, Ramakers, Inez H.G.B., De Deyn, Peter Paul, Heijboer, Annemieke C., Koek, Huiberdina L., OldeRikkert, Marcel G.M., Papma, Janne M., Reesink, Fransje E., Smits, Lieke L., Stehouwer, Coen D.A., Teunissen, Charlotte E., Verhey, Frans R.J., van der Flier, Wiesje M., Biessels, Geert Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734123/ https://www.ncbi.nlm.nih.gov/pubmed/29154275 http://dx.doi.org/10.3233/JAD-170522

Ejemplares similares

The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
por: Aalten, Pauline, et al.
Publicado: (2014)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease
por: van de Beek, Marleen, et al.
Publicado: (2019)

Cognitive and functional progression of dementia in two longitudinal studies
por: Wang, Yuwei, et al.
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

A comparison of two approaches for modeling dementia progression in a changing patient context
por: Wubben, Nina, et al.
Publicado: (2022)

Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer’s disease
por: Bron, Esther E., et al.
Publicado: (2021)

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2017)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study
por: Handels, Ron LH, et al.
Publicado: (2012)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands
por: Liao, Weiqi, et al.
Publicado: (2016)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023)

A Scoping Review of Communicating Neuropsychological Test Results to Patients and Family Members
por: Gruters, Angélique AA, et al.
Publicado: (2021)

Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone
por: Yosypyshyn, Dariia, et al.
Publicado: (2023)

Development of memory clinics in the Netherlands over the last 20 years
por: Gruters, Angélique A.A., et al.
Publicado: (2019)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Value of CSF-Cl, CSF-GS, CSF-MALB, and CSF-ADA in Differential Diagnosis of Secondary Hydrocephalus
por: Huang, Junzhang, et al.
Publicado: (2022)

CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
por: van der Ende, Emma L, et al.
Publicado: (2023)

Retracted: Value of CSF-Cl, CSF-GS, CSF-MALB, and CSF-ADA in Differential Diagnosis of Secondary Hydrocephalus
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

Physical Performance in Memory Clinic Patients: The Potential Role of the White Matter Network
por: Verwer, Jurre H., et al.
Publicado: (2019)

G-CSF and GM-CSF in clinical trials.
por: Antman, K. H.
Publicado: (1990)

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2018)

In-depth Characterization of the Cerebrospinal Fluid (CSF) Proteome Displayed Through the CSF Proteome Resource (CSF-PR)
por: Guldbrandsen, Astrid, et al.
Publicado: (2014)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

A role for G-CSF and GM-CSF in nonmyeloid cancers
por: Aliper, Alexander M, et al.
Publicado: (2014)

CSF protein variations correlates with CSF oscillations in hydrocephalus patients
por: Balédent, Olivier, et al.
Publicado: (2015)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
por: Abdullah, Laila, et al.
Publicado: (2020)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2020)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_up2ud35242ma6benn3n62mdbcr